AstraZeneca signed a licensing deal with CSPC Pharmaceuticals worth up to $18.5 billion (some reports cite $4.7 billion total value) for eight obesity and type 2 diabetes programs, including long-acting injectables like once-monthly SYH2082 GLP1RA/GIPR agonist entering Phase I. 1 2 3 AstraZeneca pays $1.2 billion upfront, with CSPC eligible for up to $3.5 billion in development/regulatory milestones and additional payments/royalties on sales. 1 3 AstraZeneca handles development and commercialization outside China; CSPC retains rights in China, Taiwan, Hong Kong, and Macau. 1 3 Deal leverages CSPC's AI-enabled peptide tech and sustained-release platform for extended dosing to improve adherence. 1 3 Announced around January 29-30, 2026, alongside AstraZeneca's $15 billion investment in China by 2030. 1 2 3 Bolsters AstraZeneca's obesity pipeline, which includes elecoglipron (oral GLP1RA), weekly injectables, and other assets, amid a market projected to reach $173.5 ...
- Get link
- X
- Other Apps